LSI USA '23 filling fast. Register Now

Kasper Bourdette, Acorai - Heart Failure Management | LSI Europe '22

Speakers

Kasper Bourdette

Kasper Bourdette

Head of Commercialization, Acorai
Read Biography
Acorai is developing a non-invasive monitoring solution to measure pulmonary artery pressure. The handheld device utilizes a unique combination of acoustic, electrocardiographic, pressure, seismic and visual sensors to collect robust data to be analyzed using a machine learning engine to evaluate heart failure progression.

Transcription

Kasper Bourdette  0:06  

All right, thank you. So hi, everyone. I'm Kasper, a co founder of Acorai. We're a Swedish founded company. And we are working on what we believe it can become the new standard in heart failure management. So here's the quick background off the heart failure space. It's a vast global disease area, which costs healthcare systems, over 300 billion US dollars every year. It's affecting 60 million patients globally. And it's diseases, which is very difficult in accurately diagnosing and monitoring, which incurs a lot of issues for the heart, health care professionals. What this means is that patients are discharged too early often. And up to 50% of patients are readmitted within six months of leaving the care facilities. What this of course results in is a massive increase in costs for healthcare system and inefficiencies in the system. So what can you do about this? Well, it's been proven that to improve the discharge decisions, as well as reduce the number of readmissions, with up to as much as 75%. You can do this by measuring the intracardiac pressures, what's also committed called the blood pressures within the heart. So it's so efficient. So why are we not doing that at a massive scale? Well, the thing is that all the current intracardiac pressure monitoring solutions in the market are invasive, mainly, they require surgery. What this results in is, of course, high costs, which in the end results in limited applicability and widespread use across healthcare systems. So as we were looking at this market, we realized that there's a need for a low costs, non invasive and accurate solution for measuring these pressures. And this is where we come in, we have to cry, we have developed the world's first non invasive handheld intracardiac blood pressure monitoring device. So it's in the form factor of a smartphone. And it can measure these inter cardio pressures without surgery, just by holding the device against the heart for a few minutes. These measurements reach accuracies equivalent of the invasive gold standards. And we believe that this will be able to improve care, improve health outcomes, and save drastic amounts of money for the healthcare systems globally. So how do we achieve this? Well, we're utilizing what we call the patented save sensor technology system, which is a combination of four sensors, systems, the system, your Cardiography, acoustic PSD, sensors, visual PPG sensor, as well as electric Cardiography. The richness of data we gather, combined with machine learning models, and the data that we gather in our clinical studies from invasive procedures enable us to present the resulting cardiac insights presented here on the right hand side, namely right atrial pressures, pulmonary artery pressures, as well as pulmonary capillary pressures. So to give you a bit more background of where we are in the clinical phase, so this is results from our first pilot study, in which we have admitted over 150 patients with these patients who were already demonstrating 95% of our measurement differences falling within the clinically acceptable limits. And that's comparing to the invasive gold standards. We're also showcasing improved performance in identifying congested patients, as opposed to the standard of care established as of today. This first study the pilot study, and it's closing down on the end of the year. And in the beginning of next year, we're starting our larger global generalization study in which we are populating five to 50 patients across a wide range of demography. So we will able to enable a robust machine learning model in our file and product. This is what I like to call the bit of a bragging slide. But as we realize these initial promising results. We've talked to a lot of cardiologists and people in this space about the results. And I'm not going to go through all of this. If you're in the heart center space, you might recognize a few of the people but I will highlight my favorite quotes here from Dr. Shaheen Rao in the top right corner, who said If my hospital doesn't buy this out by myself, and to me, that's probably the best verdict you can get from a practitioner. Do note that she said this before joining our clinical advisory board, so it's. But just to give you a bit more insight into the overall market size and how it looks, I touched upon it briefly in the beginning of the discussion. It's a major global issue, there are over 60 million patients suffering a heart failure. And the prevalence is growing rapidly and it's going to continue to grow rapidly over the coming 10 years. Were targeted initial market launch in the US markets already 2020 for a retargeting. inpatients use. So we want to get this device into the hands of petitioning cardiologists we want we want to help them diagnose triage implant treatments for heart failure patients, and for this, there's no reimbursement needed, we're looking to go to mark that pricing level of roughly 7.5 to 10k US dollars. And this includes a subscription cost of roughly 6k per year. In the longer term, we're also having an R&D pipeline development of a remote application so that we will be able to cover the entire end and span for heart failure patients. So having this device in the clinics for cardiologists, but also remote monitoring patients when they're at home. To give a bit of an overview of what the current market landscape looks like, we categorize our competitors into direct competitors, which are the ones that are able to measure with accuracies equivalent to the invasive gold standard. The only products in this category today, it is invasive, remote heart failure monitoring devices. So these requires surgery to come at a high cost. And they're not applicable for inpatient settings. We also have the indirect competitors, which technologies do not really meet the same accuracies or the gold standards. And they would do have a set of non invasive remote monitoring solutions, which namely only target to remote applications. And they're only designed for single patients use. We also have them the non invasive in hospital heart failure monitoring solutions, which we see often discussions which cardiologists are a bit less preferred preferred since they provide indices as opposed to the absolute pressure measurements which we can generate. We're a Swedish co founding team. It's me, Kasper, Jacob and Philip. And we've surrounded ourselves with a global team with global experience and launching cardiology products. We have a world leading clinical and corporate advisory board. And we are currently in the midst of raising a 10 million round that's going to last us until 2025 and a market reach. We are in in interesting discussions with distributor licensees and so tedious globally and if you find me here or want to reach out it's feel free to reach out to me or anyone in my team. Thank you very much.

 

 

 

 

Join us at the next LSI Emerging Medtech Summit

LSI's global events attract top innovators, active investors, and deal-making strategics.

GET INFO

Share this video

Our Clients